Multiple, sequential light, laser sources no benefit in rosacea

Multiple, sequential light, laser sources no benefit in rosacea

(HealthDay)—Use of multiple, sequential light and laser sources to activate aminolevulinic acid (ALA) in photodynamic therapy (PDT) does not lead to statistically significant improvements in patient outcome for rosacea, according to a study published online July 4 in the Journal of Cosmetic Dermatology.

Daniel P. Friedmann, M.D., from Westlake Dermatology & Cosmetic Surgery in Austin, Texas, and colleagues examined ALA-PDT for using sequentially with red light, pulsed-dye laser (PDL), and/or intense pulsed light (IPL) in a retrospective study involving 39 patients. Treatment groups were: blue light + PDL; blue light + IPL; blue light + PDL + IPL; and blue light + red light + PDL + IPL. A telephone questionnaire was used to obtain patient-reported outcome measures.

The researchers found that patient-reported rosacea and overall skin quality improvement were not significantly different between the groups. The only significant difference in post-procedure adverse events was decreased peeling following blue light + IPL compared with blue light + PDL (P = 0.041) and blue light + IPL + PDL (P = 0.005).

"The use of multiple, sequential light and sources with ALA-PDT for rosacea, while well tolerated, did not lead to statistically significant improvements in patient-reported efficacy," the authors write.


Explore further

Pulsed dye laser effective on port-wine stains in infants

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Multiple, sequential light, laser sources no benefit in rosacea (2016, July 18) retrieved 31 July 2021 from https://medicalxpress.com/news/2016-07-multiple-sequential-laser-sources-benefit.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments